These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 12928941

  • 21. Preventing joint damage as the best measure of biologic drug therapy.
    Bresnihan B.
    J Rheumatol Suppl; 2002 Sep; 65():39-43. PubMed ID: 12236622
    [Abstract] [Full Text] [Related]

  • 22. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
    Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D.
    Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
    [Abstract] [Full Text] [Related]

  • 23. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.
    Cohen SB, Strand V, Aguilar D, Ofman JJ.
    Rheumatology (Oxford); 2004 Jun; 43(6):704-11. PubMed ID: 14997006
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions.
    Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, Liu T, Solinger AM.
    Arthritis Rheum; 2004 Jun; 50(6):1752-60. PubMed ID: 15188350
    [Abstract] [Full Text] [Related]

  • 26. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
    Fleishmann RM.
    Clin Exp Rheumatol; 2002 Jun; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V, Kavanaugh AF.
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [Abstract] [Full Text] [Related]

  • 29. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives.
    Bresnihan B.
    Clin Exp Rheumatol; 2002 Jun; 20(5 Suppl 27):S32-4. PubMed ID: 14989427
    [Abstract] [Full Text] [Related]

  • 30. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.
    Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Dasou P, Parissis J, Nikolaou M, Markantonis SL, Katsimbri P, Skarantavos G, Andreadou I, Anastasiou-Nana M.
    Thromb Haemost; 2011 Nov; 106(5):959-67. PubMed ID: 21947196
    [Abstract] [Full Text] [Related]

  • 31. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.
    Cohen SB, Woolley JM, Chan W, Anakinra 960180 Study Group.
    J Rheumatol; 2003 Feb; 30(2):225-31. PubMed ID: 12563672
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol.
    Langer HE, Missler-Karger B.
    Int J Clin Pharmacol Res; 2003 Feb; 23(4):119-28. PubMed ID: 15224501
    [Abstract] [Full Text] [Related]

  • 34. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis.
    Bresnihan B, Cobby M.
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii22-8. PubMed ID: 12817092
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH, Bingham SJ, Seto Y, McGonagle D, Bejarano V, White J, Emery P.
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis.
    Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M.
    Ann Rheum Dis; 2005 Apr; 64(4):630-3. PubMed ID: 15345502
    [Abstract] [Full Text] [Related]

  • 39. Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice.
    den Broeder AA, de Jong E, Franssen MJ, Jeurissen ME, Flendrie M, van den Hoogen FH.
    Ann Rheum Dis; 2006 Jun; 65(6):760-2. PubMed ID: 16269431
    [Abstract] [Full Text] [Related]

  • 40. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J, Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.